Fluorescence guided surgery, augmented reality, and intra-operative imaging devices are rapidly pervading the field of surgical interventions, equipping the surgeon with powerful tools capable of enhancing the surgical visualisation of anatomical normal and pathological structures. There is a wide range of possibilities in the adult population to use these novel technologies and devices in the guidance for surgical procedures and minimally invasive surgeries. Their applications and their use have also been increasingly growing in the field of paediatric surgery, where the detailed visualisation of small anatomical structures could reduce procedure time, minimising surgical complications and ultimately improve the outcome of surgery. This review aims to illustrate the mechanisms underlying these innovations and their main applications in the clinical setting.

Fluorescence-guided surgery is set to play a pivotal role in the intraoperative management of pediatric tumors. Shortwave infrared imaging (SWIR) has advantages over conventional near-infrared I (NIR-I) imaging with reduced tissue scattering and autofluorescence. Here, two NIR-I dyes (IRDye800CW and IR12), with long tails emitting in the SWIR range, were conjugated with a clinical-grade anti-GD2 monoclonal antibody (dinutuximab-beta) to compare NIR-I and SWIR imaging for neuroblastoma surgery. A first-of-its-kind multispectral NIR-I/SWIR fluorescence imaging device was constructed to allow an objective comparison between the two imaging windows. Conjugates were first characterized in vitro. Tissue-mimicking phantoms, imaging specimens of known geometric and material composition, were used to assess the sensitivity and depth penetration of the NIR-I/SWIR device, showing a minimum detectable volume of ∼0.9 mm3 and depth penetration up to 3 mm. In vivo, fluorescence imaging using the NIR-I/SWIR device showed a high tumor-to-background ratio (TBR) for both dyes, with anti–GD2-IR800 being significantly brighter than anti–GD2-IR12. Crucially, the system enabled higher TBR at SWIR wavelengths than at NIR-I wavelengths, verifying SWIR imaging enables high-contrast delineation of tumor margins. This work demonstrates that by combining the high specificity of anti-GD2 antibodies with the availability and translatability of existing NIR-I dyes, along with the advantages of SWIR in terms of depth and tumor signal-to-background ratio, GD2-targeted NIR-I/SWIR-guided surgery could improve the treatment of patients with neuroblastoma, warranting investigation in future clinical trials. Significance: Multispectral near-infrared I/shortwave infrared fluorescence imaging is a versatile system enabling high tumor-to-background signal for safer and more complete resection of pediatric tumors during surgery.

SignificanceHyperspectral imaging (HSI) is a promising real-time, non-invasive, non-ionizing optical imaging technique. In surgical oncology, HSI can capture both structural and functional tissue information, allowing the characterization of tumor lesions both intraoperatively and on a histopathological level.AimWe review the latest technological and clinical advancements of HSI as a guidance tool for tumor resection.ApproachFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically searched MEDLINE, Embase, and Web of Science using logical keyword combinations related to “hyperspectral imaging” and “surgical oncology.” Eighty-five articles published between January 1, 2014, and April 30, 2024, were selected based on predefined inclusion and exclusion criteria. Technical and clinical data were extracted and analyzed.ResultsThe reviewed studies include preclinical and clinical investigations involving various tumor models and 2163 patients, including 24 pediatric cases. HSI has demonstrated broad applicability across various anatomical regions in both ex vivo and in vivo settings, with its most valuable application being tumor tissue delineation.ConclusionsHSI remains in its early technological stages, requiring high-quality evidence and multidisciplinary collaboration to support clinical adoption. A deeper understanding and improved characterization of biological tissue hyperspectral properties are essential to better inform and orient future hardware and software designs.

Background: High‐risk neuroblastoma (HR‐NB) has a variable response to preoperative chemotherapy. It is not possible to differentiate viable vs. nonviable residual tumor before surgery.Purpose: To explore the association between apparent diffusion coefficient (ADC) values from diffusion‐weighted magnetic resonance imaging (DW‐MRI), ¹²³I‐meta‐iodobenzyl‐guanidine (¹²³I‐mIBG) uptake, and histology before and after chemotherapy.Study Type: Retrospective.Subjects: Forty patients with HR‐NB.Field Strength/Sequence: 1.5T axial DW‐MRI (b = 0,1000 s/mm²) and T₂‐weighted sequences. ¹²³I‐mIBG scintigraphy planar imaging (all patients), with additional ¹²³I‐mIBG single‐photon emission computed tomography / computerized tomography (SPECT/CT) imaging (15 patients).Assessment: ADC maps and ¹²³I‐mIBG SPECT/CT images were coregistered to the T₂‐weighted images. ¹²³I‐mIBG uptake was normalized with a tumor‐to‐liver count ratio (TLCR). Regions of interest (ROIs) for primary tumor volume and different intratumor subregions were drawn. The lower quartile ADC value (ADC_25prc) was used over the entire tumor volume and the overall level of ¹²³I‐mIBG uptake was graded into avidity groups.Statistical Tests: Analysis of variance (ANOVA) and linear regression were used to compare ADC and MIBG values before and after treatment. Threshold values to classify tumors as viable/necrotic were obtained using ROC analysis of ADC and TLCR values.Results: No significant difference in whole‐tumor ADC_25prc values were found between different ¹²³I‐mIBG avidity groups pre‐ (P = 0.31) or postchemotherapy (P = 0.35). In the “intratumor” analysis, 5/15 patients (prechemotherapy) and 0/14 patients (postchemotherapy) showed a significant correlation between ADC and TLCR values (P < 0.05). Increased tumor shrinkage was associated with lower pretreatment tumor ADC_25prc values (P < 0.001); no association was found with pretreatment ¹²³I‐mIBG avidity (P = 0.17). Completely nonviable tumors had significantly lower postchemotherapy ADC_25prc values than tumors with >10% viable tumor (P < 0.05). Both pre‐ and posttreatment TLCR values were significantly higher in patients with >50% viable tumor than those with 10–50% viable tumor (P < 0.05).Data Conclusion: ¹²³I‐mIBG avidity and ADC values are complementary noninvasive biomarkers of therapeutic response in HR‐NB.Level of Evidence: 4.Technical Efficacy Stage: 3.

Despite aggressive treatments, the prognosis of high-risk NB remains poor. Surgical oncology needs innovative intraoperative devices to help surgeons discriminate malignant tissue from necrotic and surrounding healthy tissues. Changes within the tumor vasculature could be used intraoperatively as a diagnostic tool to guide surgical resection. Here, we retrospectively analyzed the mean vascular density (MVD) of different NB subtypes at diagnosis and after induction chemotherapy using scanned histological samples. One patient was prospectively enrolled, and an ex vivo photoacoustic imaging (PAI) scan was performed on two representative sections to assess its capacity to discriminate different tumor regions. We found that post-chemotherapy, viable areas of differentiating NBs and ganglioneuroblastomas are associated with higher MVD compared to poorly differentiated NBs. Early necrotic regions showed higher MVD than late necrotic and viable regions. Finally, calcified areas showed significantly lower MVD than any other histological component. The acquired PAI images showed a good high-resolution ex vivo 3D delineation of NB margins. Overall, these results suggest that a high-definition preclinical imaging device such as PAI could potentially be exploited to guide surgical resection by identifying different vasculature signatures.